An in vivo antilymphatic screen in zebrafish identifies novel inhibitors of mammalian lymphangiogenesis and lymphatic-mediated metastasis

Molecular Cancer Therapeutics

Volumn 13, Issue 10, 2014, Pages 2450-2462

  Astin, Jonathan W ^a   Jamieson, Stephen M F ^b,c   Eng, Tiffany C Y ^a,b   Flores, Maria V ^a   Misa, June P ^a   Chien, Annie ^a   Crosier, Kathryn E ^a,c   Crosier, Philip S ^a,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CINNARIZINE; FLUNARIZINE; KAEMPFEROL; LEFLUNOMIDE; ANTINEOPLASTIC AGENT; ISOXAZOLE DERIVATIVE; KAEMPFEROL DERIVATIVE; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BREAST METASTASIS; CANCER PREVENTION; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; IN SITU HYBRIDIZATION; IN VIVO STUDY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ZEBRA FISH; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; ENDOTHELIUM CELL; HUMAN; LYMPH NODE; NEOPLASMS; PATHOLOGY; RANDOMIZATION; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CINNARIZINE; ENDOTHELIAL CELLS; FEMALE; FLUNARIZINE; HUMANS; ISOXAZOLES; KAEMPFEROLS; LYMPH NODES; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MICE; MICE, INBRED C57BL; NEOPLASMS; RANDOM ALLOCATION; RECEPTOR PROTEIN-TYROSINE KINASES; ZEBRAFISH;

EID: 84923226649     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0469-T     Document Type: Article

References (50)

1. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer 2003;98:413-23.
2. Sundlisaeter E, Dicko A, Sakariassen PO, Sondenaa K, Enger PO, Bjerkvig R. Lymphangiogenesis in colorectal cancer-prognostic and therapeutic aspects. Int J Cancer 2007;121:1401-9.
3. Alitalo A, Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2012;31:4499-508.
4. Achen MG, McColl BK, Stacker SA. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 2005;7:121-7.
5. Christiansen A, Detmar M. Lymphangiogenesis and cancer. Genes Cancer 2011;2:1146-58.
6. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003;162:1951-60.
7. Kerjaschki D, Regele HM, Moosberger I, Nagy-Bojarski K, Watschinger B, Soleiman A, et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infi ltrates. J Am Soc Nephrol 2004;15:603-12.
8. Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009;15:1023-30.
9. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 2005;65:4739-46.
10. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007;109:1010-7.
11. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005;201:1089-99.
12. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8.
13. Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008;13:331-42.
14. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 2005;65:6901-9.
15. Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006;66:2650-7.
16. Alam A, Blanc I, Gueguen-Dorbes G, Duclos O, Bonnin J, Barron P, et al. SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities. Mol Cancer Ther 2012;11:1637-49.
17. Hogan BM, Herpers R, Witte M, Helotera H, Alitalo K, Duckers HJ, et al. Vegfc/Flt4 signalling is suppressed by Dll4 in developing zebrafish intersegmental arteries. Development 2009;136:4001-9.
18. Koltowska K, Betterman KL, Harvey NL, Hogan BM. Getting out and about: the emergence and morphogenesis of the vertebrate lymphatic vasculature. Development 2013;140:1857-70.
19. Kuchler AM, Gjini E, Peterson-Maduro J, Cancilla B, Wolburg H, Schulte-Merker S. Development of the zebrafish lymphatic system requires VEGFC signaling. Curr Biol 2006;16:1244-8.
20. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 2005;4:35-44.
21. Bussmann J, Bos FL, Urasaki A, Kawakami K, Duckers HJ, Schulte-Merker S. Arteries provide essential guidance cues for lymphatic endothelial cells in the zebra fish trunk. Development 2010;137:2653-7.
22. Tran TC, Sneed B, Haider J, Blavo D, White A, Aiyejorun T, et al. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafi sh. Cancer Res 2007;67:11386-92.
23. Wang C, Tao W, Wang Y, Bikow J, Lu B, Keating A, et al. Rosuvastatin, identified from a zebra fish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur Urol 2010;58:418-26.
24. Buchanan CM, Shih JH, Astin JW, Rewcastle GW, Flanagan JU, Crosier PS, et al. DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular. Clin Sci 2012;122:449-57.
25. Flores MV, Hall CJ, Crosier KE, Crosier PS. Visualization of embryonic lymphangiogenesis advances the use of the zebrafish model for research in cancer and lymphatic pathologies. Dev Dyn 2010;239:2128-35.
26. Okuda KS, Astin JW, Misa JP, Flores MV, Crosier KE, Crosier PS. lyve1 expression reveals novel lymphatic vessels and new mechanisms for lymphatic vessel development in zebrafish. Development 2012;139:2381-91.
27. Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 2002;248:307-18.
28. Lam EY, Hall CJ, Crosier PS, Crosier KE, Flores MV. Live imaging of Runx1 expression in the dorsal aorta tracks the emergence of blood progenitors from endothelial cells. Blood 2010;116:909-14.
29. Kaufman CK, White RM, Zon L. Chemical genetic screening in the zebrafish embryo. Nat Protoc 2009;4:1422-32.
30. Astin JW, Haggerty MJ, Okuda KS, Le Guen L, Misa JP, Tromp A, et al. Vegfd can compensate for loss of Vegfc in zebrafish facial lymphatic sprouting. Development 2014;141:2680-90.
31. Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007;71:771-7.
32. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007;98:726-33.
33. Schulz MM, Reisen F, Zgraggen S, Fischer S, Yuen D, Kang GJ, et al. Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis. Proc Natl Acad Sci U S A 2012;109:E2665-74.
34. Bartlett RR, Dimitrijevic M, Mattar T, Zielinski T, Germann T, Rude E, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991;32:10-21.
35. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996;35:1270-3.
36. Schledzewski K, Falkowski M, Moldenhauer G, Metharom P, Kzhyshkowska J, Ganss R, et al. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumors and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J Pathol 2006;209:67-77.
37. Calderon-Montano JM, Burgos-Moron E, Perez-Guerrero C, Lopez-Lazaro M. A review on the dietary flavonoid kaempferol. Mini Rev Med Chem 2011;11:298-344.
38. Cui Y, Morgenstern H, Greenland S, Tashkin DP, Mao JT, Cai L, et al. Dietary flavonoid intake and lung cancer-a population-based case-control study. Cancer 2008;112:2241-8.
39. Nothlings U, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN. Flavonols and pancreatic cancer risk: the multiethnic cohort study. Am J Epidemiol 2007;166:924-31.
40. Gates MA, Tworoger SS, Hecht JL, De Vivo I, Rosner B, Hankinson SE. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int J Cancer 2007;121:2225-32.
41. Luo H, Rankin GO, Juliano N, Jiang BH, Chen YC. Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFkappaB-cMyc-p21 pathway. Food Chem 2012;130:321-8.
42. Luo H, Rankin GO, Liu L, Daddysman MK, Jiang BH, Chen YC. Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer 2009;61:554-63.
43. McLean JE, Neidhardt EA, Grossman TH, Hedstrom L. Multiple inhibitor analysis of the brequinar and le flunomide binding sites on human dihydroorotate dehydrogenase. Biochemistry 2001;40:2194-200.
44. Williamson RA, Yea CM, Robson PA, Curnock AP, Gadher S, Hambleton AB, et al. Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995;270:22467-72.
45. Kaplan MJ. Leflunomide Aventis Pharma. Curr Opin Investig Drugs 2001;2:222-30.
46. White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 2011;471:518-22.
47. Opie LH, Buhler FR, Fleckenstein A, Hansson L, Harrison DC, Poole-Wilson PA, et al. International society and federation of cardiology: working group on classification of calcium antagonists for cardiovascular disease. Am J Cardiol 1987;60:630-2.
48. Kalin RE, Banziger-Tobler NE, Detmar M, Brandli AW. An in vivo chemical library screen in Xenopus tadpoles reveals novel pathways involved in angiogenesis and lymphangiogenesis. Blood 2009;114:1110-22.
49. Kaelin WG Jr, Shrivastav S, Jirtle RL. Blood flow to primary tumors and lymph node metastases in SMT-2A tumor-bearing rats following intravenous flunarizine. Cancer Res 1984;44:896-9.
50. Dewhirst MW, Ong ET, Madwed D, Klitzman B, Secomb T, Brizel D, et al. Effects of the calcium channel blocker flunarizine on the hemodynamics and oxygenation of tumor microvasculature. Radiat Res 1992;132:61-8.